4//SEC Filing
ROTE WILLIAM E. 4
Accession 0001415889-24-023096
CIK 0001438533other
Filed
Sep 8, 8:00 PM ET
Accepted
Sep 9, 9:20 PM ET
Size
7.4 KB
Accession
0001415889-24-023096
Insider Transaction Report
Form 4
ROTE WILLIAM E.
SENIOR VICE PRESIDENT, R&D
Transactions
- Sale
Common Stock
2024-09-09$11.52/sh−4,387$50,538→ 84,455 total - Award
Common Stock
2024-09-05+6,750→ 88,842 total
Footnotes (3)
- [F1]On January 31, 2023, the reporting person was granted performance restricted stock units (PSUs) covering 6,750 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On September 5, 2024, the PSUs vested upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted full approval to FILSPARI (sparsentan) in IgA Nephropathy.
- [F2]Includes 1,372 shares of Common Stock that were acquired by the Reporting Person on May 31, 2024 pursuant to the Issuer's Employee Stock Purchase Plan.
- [F3]This sale was made pursuant to a written plan adopted March 15, 2024 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.
Documents
Issuer
Travere Therapeutics, Inc.
CIK 0001438533
Entity typeother
Related Parties
1- filerCIK 0001698262
Filing Metadata
- Form type
- 4
- Filed
- Sep 8, 8:00 PM ET
- Accepted
- Sep 9, 9:20 PM ET
- Size
- 7.4 KB